PCNT and atherosclerosis: Given that the mechanistic pathway identified here to drive augmented atherosclerosis with pericentrin loss is dependent on SMC cholesterol biosynthesis, statins provide a targeted therapy to block the pathway specifically in patients with MOPDII.